Keyphrases
Crohn's Disease
100%
Inflammatory Bowel Disease
98%
Ulcerative Colitis
94%
Placebo
38%
Infliximab
25%
Vedolizumab
25%
Clinical Remission
24%
Induction Therapy
20%
Maintenance Therapy
19%
Ustekinumab
18%
Active Ulcerative Colitis
17%
Confidence Interval
17%
Clinical Trials
16%
Moderate to Severe
16%
Tofacitinib
15%
Clinical Response
14%
Active Crohn's Disease
14%
Crohn's Colitis
13%
Disease Activity
12%
Remission
12%
Crohn's Disease Activity Index
10%
Randomized Double-blind
10%
Adverse Events
10%
Corticosteroids
9%
Mirikizumab
9%
Colitis
8%
Randomized Placebo-controlled Trial
8%
Mucosal Healing
8%
Severe Ulcerative Colitis
8%
Crohn's
8%
Newly Diagnosed
7%
Randomized Controlled Trial
7%
Mayo Score
7%
Endoscopy
7%
Colectomy
7%
Guselkumab
7%
Histologic
7%
Placebo-controlled
7%
Serious Adverse Events
6%
Risk Factors
6%
Interleukin-23 (IL-23)
6%
Odds Ratio
6%
Open-label Extension
6%
Etrasimod
6%
Ulcerative Colitis Patient
6%
United States
6%
Adalimumab
6%
Endoscopic Remission
6%
Tumor Necrosis Factor Antagonist
6%
Phase II Study
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
97%
Crohn's Disease
88%
Inflammatory Bowel Disease
63%
Placebo
46%
Remission
43%
Diseases
23%
Vedolizumab
21%
Infliximab
20%
Disease Activity
19%
Adverse Event
18%
Ustekinumab
17%
Combination Therapy
17%
Tofacitinib
15%
Clinical Trial
14%
Tumor Necrosis Factor
12%
Biological Product
8%
Infection
7%
Guselkumab
7%
Randomized Controlled Trial
7%
Inflammation
6%
Mirikizumab
6%
Colitis
6%
Etrasimod
6%
Immunomodulating Agent
5%
Medicine and Dentistry
Inflammatory Bowel Disease
76%
Ulcerative Colitis
66%
Crohn's Disease
64%
Diseases
23%
Vedolizumab
21%
Placebo
21%
Disease Activity
14%
Patient with Inflammatory Bowel Disease
14%
Clinical Trial
13%
Patient with Ulcerative Colitis
13%
Patient with Crohn's Disease
13%
Infliximab
12%
Tumor Necrosis Factor
11%
Combination Therapy
10%
Maintenance Therapy
9%
Colitis
8%
Adverse Event
8%
Endoscopy
8%
Systematic Review
8%
Quality of Life
7%
Mirikizumab
7%
Randomized Controlled Trial
7%
Biological Product
6%
Colectomy
6%
Odds Ratio
6%
Biological Therapy
5%
Biological Marker
5%
Recurrent Disease
5%
Meta-Analysis
5%